Clinical efficacy of alternative antiandrogen therapy in Japanese men with relapsed prostate cancer after first-line hormonal therapy

International Journal of Urology

Volumn 14, Issue 2, 2007, Pages 128-132

  Okihara, Koji ^a   Ukimura, Osamu ^a   Kanemitsu, Noriyuki ^a   Mizutani, Yoichi ^a   Kawauchi, Akihiro ^a   Miki, Tsuneharu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Alternative antiandrogen; Antiandrogen withdrawal syndrome; Prostate cancer; Relapse

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CHLORMADINONE; FLUTAMIDE; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CORRELATION ANALYSIS; DRUG EFFICACY; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; WITHDRAWAL SYNDROME;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; GONADOTROPIN-RELEASING HORMONE; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; SURVIVAL RATE; TREATMENT FAILURE;

EID: 33846277664     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2007.01698.x     Document Type: Article

References (13)

1. Crawford ED. Epidemiology of prostate cancer. Urology 2003; 62 (Suppl. 6A): 3-12.
2. The Research Group for Population-based Cancer Registration in Japan. Cancer incidence and incidence rates in Japan 1999: estimates based on data from 11 population-based cancer registries. Jpn. J. Clin. Oncol. 2004; 34: 352-6.
3. Cancer Registration Committee of the Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int. J. Urol. 2005; 12: 46-61.
4. Sher HI, Liebertz C, Kelly WK et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J. Clin. Oncol. 1997; 15: 2928-38.
5. Kojima S, Suzuki H, Akakura K, Shimbo M, Ichikawa T, Ito H. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J. Urol. 2004; 171 (2 Pt 1): 679-83.
6. Nieh PT. Withdrawal phenomenon with the antiandrogen casodex. J. Urol. 1995; 153: 1070-2.
7. Harmanker P, Hutter RVP, Sobin LH, Wager G, Witteking Ch. Prostate. In: TNM Atlas, 4th edn. Springer Verlag, New York, 1997; 272.
8. Joyce R, Fenton MA, Rode P et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J. Urol. 1998; 159: 149-53.
9. Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS. Secondary hormonal therapy for advanced prostate cancer. J. Urol. 2006; 175: 27-34.
10. Kelly WK, Scher HI. Prostate specific antiandrogen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J. Urol. 1993; 149: 607-9.
11. Suzuki H, Nihei N, Sato N, Ichikawa T, Mizokami A, Shimazaki J. Codon 877 mutation in the androgen receptor gene in advanced cancer: relation to antiandrogen withdrawal syndrome. Prostate 1996; 29: 153-8.
12. Suzuki H, Ueda T, Ichikawa T, Ito H. Androgen receptor involvement in the progression of prostate cancer. Endocr. Relat. Cancer 2003; 10: 209-16.
13. Bohl CE, Gao W, Miller DD, Bell CE, Dalton JT. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc. Natl Acad. Sci. USA 2005; 102: 6201-6.